OBSERVATIONAL STUDY TO EVALUATE EFFECT OF SAROGLITAZAR IN INDIAN DIABETIC DYSLIPIDEMIA PATIENTS

Dr Abhishek Pandey; Prof R K Jha

Volume : V, Issue : IV, April - 2016

OBSERVATIONAL STUDY TO EVALUATE EFFECT OF SAROGLITAZAR IN INDIAN DIABETIC DYSLIPIDEMIA PATIENTS

Dr Abhishek Pandey, Prof R K Jha

Abstract :

Abstract–Saroglitazar is a peroxisome proliferation activated receptor α and γ agonist, approved in India for the management of diabetic dyslipidemia. Aims: The study was to evaluate the effect of saroglitazar 4 mg once daily in diabetic dyslipidemia patients. Methods: It was an observational study. Patients having type 2 diabetes, age above 18 years, having triglyceride ≥200 mg/dl were included. Results: A total of 108 patients with mean duration of diabetes 5.65 years were included in this study. The baseline demographic profile was mean age 51 years, mean body weight 71.2 kg and mean BMI of 26.8 kg/m2. 53.2 % patients were male and 57.4 % were reported to be on statin therapy at baseline. All 108 patients were on antidiabetic medications at baseline. The baseline HbA1c value was 8.4 % and baseline triglyceride value was 322.3 mg/dl. At 3 months follow up, use of saroglitazar 4 mg led to reduction of TG (34.7 %), total Cholesterol (18%), LDL–C (16.8 %) and non–HDL (22.8%). Saroglitazar therapy lead to significant HbA1c reduction 0.8% with significant improvement in both fasting and post prandial blood glucose. There were no alteration in liver or renal enzymes, edema or weight gain were reported. Conclusions: Saroglitazar can be used in type 2 diabetic dyslipidemia patients with Hypertriglyceridemia, not controlled alone by statin therapy, offering control of lipid and glycemic parameters with acceptable safety profile.